for joining Thanks, Matt. thank us. and Good you afternoon,
results, tailwind data, to exclusive the coverage for health fusion. joint second of over I Anthem Before States. in other insurer Level has the iFuse want XX more as United cover share our Based our titanium to long-term SI to joins X million lives for on triangular largest iFuse news in some minimally Anthem amounting our see the I invasive second exclusively exclusive quarter implants than a on guidelines is XX total. reimbursement that With plans we adopted the U.S., commercial strength exciting cover over in reimbursement covered coverage, Anthem With clinical million exclusively XXX business. Anthem members, to front. our the are
which patient awareness includes We and growth solutions, will engagement, our the commercial expansion, on through capitalize XXXX surgeon and opportunity plan, infrastructure products initiatives. sales
quarter million, relentlessly growth of to In to we the $XX.X employees pleased that XXXX. report as record continue execute to had operating to revenues on Now the revenue second generated through representing of environment. this unique our XX% quarter SI-BONE compared the of quarter, a quarter. second I'm
revenue Sequentially, for grew underlying second due our and was quarter impacted quarter COVID. our significantly As solutions. demand products to a reminder, the X% prior by year by increased
our normalizes, us give results operating space. of environment strong will our the the multibillion-dollar accelerate second quarter sacropelvic in portfolio Our opportunity in that the industry-leading confidence diverse the capture as
Now provide expansion. extend our of At our organization XXX of look the sales key the on specialists. territory end durable leadership clinical XX as infrastructure to growth position starting we and quarter, initiatives an long-term update growth, our sales XX support let was with person me and comprised managers drive
We our continue to about clinical support and of be strategic territory mix managers specialists.
Specifically, future specialists while ground revenue our serving territory to crucial an support managers. as for our clinical important for driving are also managers training productivity territory
support of to of X as total Additionally, July our added the we U.S. our regions surgeons. continue for a X, to sales expand methodically new XX organization regions And in
our the sales all-time number to an training high. portfolio engagement. significant surgeon active of drove organization, Moving The in to and surgeons a investment approximately XXX, infrastructure product on in quarter expanded in our increase the
surgeons During only allowed us the to than adoption. deployed for of in and SImulators, SImulators including the accounted SImulators but efficiently, with had not in worldwide, reengage XX which half drive trainings quarter, XX U.S. we new the inactive our more quarter, also surgeons train
the surgeons. easing, SImulator to believe training of travel combination and with continue engagement inactive forward, we and previously surgeon local will new Going restrictions for training drive in-person
are X,XXX and approximately procedure a to completed spine been U.S., surgeons date. have we X,XXX the a trained As targeting reminder, in the of which
a to showed Turning trial results with at sustained for patient results SI study marked XX% at pain, function XX% results The Clinical iFuse-XD reduction iFuse. baseline months at pain, joint opioids significant SI and and proportion products taking XX quality subjects joint improvement recently demonstrated solutions, from joint months. multicenter XX our We of to of SALLY, X-year the life. in pain. for SI of starting and announced chronic prospective in
from demonstrating XX-month are CT of joint tests; raise, bony fusion. safety, joints effectiveness, analysis across statistically up X included to improvements treated of significant benefits joint. the results of joints SI An biomechanical substantiating earlier and In XXX% economic and publication and integration to and all on timed transitional our leg SI iFuse as bony baseline. for which addition, iFuse straight or iFuse SI bridging go, joint. of active reported accelerated implant publications SALLY the the showed treated showed gold function the bridging scans There sacral sit radiographic bone showed Xx XX% showing across surface peer-reviewed stand, technology, study further from physical objective XX site iliac standard the the of both now of
on for commercial initial iFuse-TORQ with following to the Moving We're in reception its iFuse-TORQ. April. launch pleased
still While we in adoption several in trauma the early days, conversions. as are well as seeing competitive
an adult market leaders adult increase. deformity, currently highly $XX solve and market. million interest competitors growth developed And in driving key continues share. As in competitor's screw-based We bit pelvic implants preference second-generation extends a feedback scheduled. in and differentiated print iFuse-TORQ $XXX needs that primary SI of and joint as a adjacent Bedrock us the fusion testing anticipate Bedrock its was also XXXX, attractive than offer later approximately for technique the market. has million generated a primary in based unmet to revenue is design reminder, surgeons our opinion TORQ early implant, a threaded which allows that our to product, on trauma, will enter product the XD business applications a In we estimate is kind deformity to that joint our fusion. first leapfrogs previously of Last iFuse-TORQ among clinical leadership year, SI market deformity from KOLs,
capacity instrumentation instrumentation our experiencing our the issues material, the impacted times The not suppliers verification labor we to and due and adult deformity delivery our supply COVID-XX experiencing challenges raw are delay with of implants, product due with impact. validation testing, longer-than-normal chain in to we're our causing delays While second-generation some launch.
this developing to risk future. However, in mitigate we the plans are
initiatives. patient awareness our Next on to
amplifying digital second our completed marketing higher focusing care digital return TV Based XXXX. to investment and through social empowering upon our our have We revenue are program media, the marketing patient compared second half multiple and search, the marketing in initiatives. cities SI through initiatives, these on in video. display expected seeing incremental and marketing professional to we're and including toward reach broadcast to health results, investment We're journey. results test patients the digital growth These professionals a their investments fuel in of experiences,
initiatives continuously targeted, improved marketing. will allow be Our us digital for measurable allow technology-enabled, data-driven, highly to and
from revenue beginning the see in programs to expect these We impact XXXX.
established a for fusion. me SI programs care provide let health more economics. Centene XX more intermediary some privately covers invasive on both coverage government-sponsored health and is minimally joint and Effective million members. Corporation positive X, than insured Finally, Centene major July updates for
procedures provides for details provide turn coverage to French joint With insured With iFuse-XD. Health French the the now has decisions fusion on joint using implants. U.S. to from care SI decision will population now by access that, the SI-BONE's for national of fusion. minimally invasive more SI results. Anthem Anshul to I national over the and substantially Centene, reimbursement This reimbursement June, all iFuse-XD exclusively in call financial system our Ministry Internationally, the granted health
